Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1α-VEGF signaling axis

Biomaterials

Volumn 35, Issue 9, 2014, Pages 2924-2933

  Kim, Bu Kyung ^a   Kim, Bo Ram ^a   Lee, Hyun Joo ^a   Lee, Seoung Ae ^a   Kim, Byoung Jun ^a   Kim, Hong ^a   Won, Yu Sub ^a   Shon, Won Jun ^a   Lee, Na Rae ^b   Inn, Kyung Soo ^b   Kim, Bum Joon ^a  

^a Seoul National University   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Cancer; Heat shock protein 70; Heat shock protein 90; Peptide; Telomerase

Indexed keywords

CANCER; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; PEPTIDE; TELOMERASE;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, INBRED BALB C; MICE, NUDE; MONOCYTES; NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; TELOMERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84894974715     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.077     Document Type: Article

References (45)

1. Macario A.J., Conway de Macario E. Sick chaperones, cellular stress, and disease. NEngl J Med 2005, 353:1489-1501.
2. Morano K.A. New tricks for an old dog: the evolving world of Hsp70. Ann N Y Acad Sci 2007, 1113:1-14.
3. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31:164-172.
4. Ciocca D.R., Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
5. Zhou J., Schmid T., Frank R., Brune B. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. JBiol Chem 2004, 279:13506-13513.
6. Bruns A.F., Yuldasheva N., Latham A.M., Bao L., Pellet-Many C., Frankel P., et al. Aheat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair. PLoS One 2012, 7:e48539.
7. Sun J., Liao J.K. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2004, 24:2238-2244.
8. Gong W., Wang Z.Y., Chen G.X., Liu Y.Q., Gu X.Y., Liu W.W. Invasion potential of H22 hepatocarcinoma cells is increased by HMGB1-induced tumor NF-kappaB signaling via initiation of HSP70. Oncol Rep 2013, 30:1249-1256.
9. Eustace B.K., Jay D.G. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004, 3:1098-1100.
10. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004, 6:507-514.
11. Jaattela M. Over-expression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int J Cancer 1995, 60:689-693.
12. Seo J.S., Park Y.M., Kim J.I., Shim E.H., Kim C.W., Jang J.J., et al. Tcell lymphoma in transgenic mice expressing the human Hsp70 gene. Biochem Biophys Res Commun 1996, 218:582-587.
13. Volloch V.Z., Sherman M.Y. Oncogenic potential of Hsp72. Oncogene 1999, 18:3648-3651.
14. Murphy M.E. The HSP70 family and cancer. Carcinogenesis 2013, 34:1181-1188.
15. Garcia-Carbonero R., Carnero A., Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 2013, 14:e358-e369.
16. Pfosser A., Thalgott M., Buttner K., Brouet A., Feron O., Boekstegers P., et al. Liposomal Hsp90 cDNA induces neovascularization via nitric oxide in chronic ischemia. Cardiovasc Res 2005, 65:728-736.
17. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992, 51:613-619.
18. Vanbuskirk A., Crump B.L., Margoliash E., Pierce S.K. Apeptide binding protein having a role in antigen presentation is a member of the HSP70 heat shock family. JExp Med 1989, 170:1799-1809.
19. Yeh C.H., Tseng R., Hannah A., Estrov Z., Estey E., Kantarjian H., et al. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res 2010, 34:605-609.
20. Kocsis J., Madaras B., Toth E.K., Fust G., Prohaszka Z. Serum level of soluble 70-kD heat shock protein is associated with high mortality in patients with colorectal cancer without distant metastasis. Cell Stress Chaperones 2010, 15:143-151.
21. Dempsey N.C., Leoni F., Ireland H.E., Hoyle C., Williams J.H. Differential heat shock protein localization in chronic lymphocytic leukemia. JLeukoc Biol 2010, 87:467-476.
22. Den R.B., Lu B. Heat shock protein 90 inhibition: rationale and clinical potential. Ther Adv Med Oncol 2012, 4:211-218.
23. Ganji P.N., Park W., Wen J., Mahaseth H., Landry J., Farris A.B., et al. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3. Angiogenesis 2013, 16:903-917.
24. Bohonowych J.E., Peng S., Gopal U., Hance M.W., Wing S.B., Argraves K.M., et al. Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for clinical evaluation. BMC Cancer 2011, 11:520.
25. Evans C.G., Chang L., Gestwicki J.E. Heat shock protein 70 (hsp70) as an emerging drug target. JMed Chem 2010, 53:4585-4602.
26. Powers M.V., Jones K., Barillari C., Westwood I., van Montfort R.L., Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone?. Cell Cycle 2010, 9:1542-1550.
27. Massey A.J., Williamson D.S., Browne H., Murray J.B., Dokurno P., Shaw T., et al. Anovel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 2010, 66:535-545.
28. Goloudina A.R., Demidov O.N., Garrido C. Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett 2012, 325:117-124.
29. Vasef M.A., Ross J.S., Cohen M.B. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am J Clin Pathol 1999, 112:S68-S75.
30. Uchida N., Otsuka T., Shigematsu H., Maeda M., Sugio Y., Itoh Y., et al. Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 1999, 23:1127-1132.
31. Kyte J.A. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009, 18:687-694.
32. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95:1474-1482.
33. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006, 55:1553-1564.
34. Kyte J.A., Gaudernack G., Dueland S., Trachsel S., Julsrud L., Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011, 17:4568-4580.
35. Brunsvig P.F., Kyte J.A., Kersten C., Sundstrom S., Moller M., Nyakas M., et al. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011, 17:6847-6857.
36. Greten T.F., Forner A., Korangy F., N'Kontchou G., Barget N., Ayuso C., et al. Aphase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010, 10:209.
37. Lee S.A., Kim B.R., Kim B.K., Kim D.W., Shon W.J., Lee N.R., et al. Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine. Biomaterials 2013, 34:7495-7505.
38. Uehara Y. Natural product origins of Hsp90 inhibitors. Curr Cancer Drug Targets 2003, 3:325-330.
39. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegue E., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
40. Shen H.Y., He J.C., Wang Y., Huang Q.Y., Chen J.F. Geldanamycin induces heat shock protein 70 and protects against MPTP-induced dopaminergic neurotoxicity in mice. JBiol Chem 2005, 280:39962-39969.
41. Elo M.A., Kaarniranta K., Helminen H.J., Lammi M.J. Hsp90 inhibitor geldanamycin increases hsp70 mRNA stabilisation but fails to activate HSF1 in cells exposed to hydrostatic pressure. Biochim Biophys Acta 2005, 1743:115-119.
42. Reikvam H., Nepstad I., Sulen A., Gjertsen B.T., Hatfield K.J., Bruserud O. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin Investig Drugs 2013, 22:551-563.
43. Ahluwalia A., Tarnawski A.S. Critical role of hypoxia sensor-HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem 2012, 19:90-97.
44. Acker T., Plate K.H. Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk. Cell Tissue Res 2003, 314:145-155.
45. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.